{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:32:15Z","timestamp":1784046735551,"version":"3.55.0"},"reference-count":33,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Recep Tayyip Erdogan University Development Foundation","award":["02024007031026"],"award-info":[{"award-number":["02024007031026"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: The antidiabetic effect of SGLT2 inhibitors (SGLT2-is) is based on their ability to increase glucose excretion through urine by inhibiting the kidney-resident SGLT2 protein. Euglycemic diabetic ketoacidosis (EuDKA) is an uncommon but potentially life-threatening adverse effect of these medications, which are notable for their antidiabetic, cardiovascular, and renal protective properties. This study aimed to clarify the impact of SGLT2-is on demographic, clinical, and biochemical characteristics in patients with DKA. Methods: A total of 51 individuals with a diagnosis of DKA were included in the trial; 19 of these patients were treated with SGLT2-is, while 32 were not. Patients diagnosed with DKA and treated with SGLT2-is were compared to those not treated with the medication in terms of clinical, biochemical, and laboratory characteristics. Results: The age of patients utilizing SGLT2-is was statistically considerably greater than that of non-users (p &lt; 0.001). EuDKA was exclusively noted in the SGLT2-is cohort (p = 0.005). Urinary tract infections, vulvovaginitis, and genitourinary infections were substantially more prevalent among SGLT2-i users compared with non-users among both women and the overall patient group (p = 0.036, p = 0.001, p = 0.005, p = 0.003, respectively). Plasma glucose concentrations were significantly higher in SGLT2-i non-users (p = 0.006). Chloride (Cl\u2212) concentrations were elevated among SGLT2-i users (p = 0.036). Conclusions: The study findings indicate that SGLT2 inhibitors may substantially influence age, serum chloride, EuDKA, and the occurrence of genitourinary infections in individuals with DKA.<\/jats:p>","DOI":"10.3390\/ph17111553","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T03:57:04Z","timestamp":1732075024000},"page":"1553","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-3476","authenticated-orcid":false,"given":"Selin","family":"Genc","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Konya State Hospital, Konya 42250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahri","family":"Evren","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Faculty of Medicine, Inonu University, Malatya 44280, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur Selcuk","family":"Yigit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ordu State Hospital, Ordu 52200, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6231-0034","authenticated-orcid":false,"given":"Ibrahim","family":"Sahin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Memorial Sisli Hospital, Istanbul 34384, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Dayanan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Batman Training and Research Hospital, Batman 72070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-0996","authenticated-orcid":false,"given":"Aleksandra","family":"Klisic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Montenegro, 81000 Podgorica, Montenegro"},{"name":"Primary Health Care Center, Center for Laboratory Diagnostics, 81000 Podgorica, Montenegro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Erturk","sequence":"additional","affiliation":[{"name":"Department of Infection Disease, Faculty of Medicine, Recep Tayyip Erdogan University, Rize 53100, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-1534","authenticated-orcid":false,"given":"Filiz","family":"Mercantepe","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Faculty of Medicine, Recep Tayyip Erdogan University, Rize 53100, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Karamichalakis, N., Kolovos, V., Paraskevaidis, I., and Tsougos, E. (2022). A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9080236"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"A674","DOI":"10.1016\/S0735-1097(18)31215-4","article-title":"Empagliflozin Induces a Myocardial Metabolic Shift from Glucose Consumption to Ketone Metabolism that Mitigates Adverse Cardiac Remodeling and Improves Myocardial Contractility","volume":"71","author":"Ibanez","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41581-018-0001-y","article-title":"CKD in diabetes: Diabetic kidney disease versus nondiabetic kidney disease","volume":"14","author":"Anders","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nberger, E., Mihaljevi\u0107, V., Steiner, K., \u0160ari\u0107, S., Kurevija, T., Majnari\u0107, L.T., Bili\u0107 \u0106ur\u010di\u0107, I., and Canecki-Var\u017ei\u0107, S. (2023). Immunomodulatory Effects of SGLT2 Inhibitors\u2014Targeting Inflammation and Oxidative Stress in Aging. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20176671"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium\u2013glucose cotransporter inhibitors and oxidative stress: An update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41514-020-00049-0","article-title":"Molecular phenotyping of oxidative stress in diabetes mellitus with point-of-care NMR system","volume":"6","author":"Peng","year":"2020","journal-title":"npj Aging Mech. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13256-020-02607-2","article-title":"Sodium-glucose cotransporter-2-induced euglycemic diabetic ketoacidosis unmasks latent autoimmune diabetes in a patient misdiagnosed with type 2 diabetes mellitus: A case report","volume":"15","author":"Vadasz","year":"2021","journal-title":"J. Med. Case Rep."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Morace, C., Lorello, G., Bellone, F., Quartarone, C., Ruggeri, D., Giandalia, A., Mandraffino, G., Minutoli, L., Squadrito, G., and Russo, G.T. (2024). Ketoacidosis and SGLT2 Inhibitors: A Narrative Review. Metabolites, 14.","DOI":"10.3390\/metabo14050264"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ata, F., Yousaf, Z., Khan, A.A., Razok, A., Akram, J., Ali, E.A.H., Abdalhadi, A., Ibrahim, D.A., Al Mohanadi, D.H.S.H., and Danjuma, M.I. (2021). SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-89752-w"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/17843286.2020.1780390","article-title":"Euglycemic diabetic ketoacidosis in a patient with type 1 diabetes and SARS-CoV-2 pneumonia: Case-report and review of the literature","volume":"77","author":"Oriot","year":"2022","journal-title":"Acta Clin. Belgica Int. J. Clin. Lab. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/dia.2018.0356","article-title":"Reversal of ketosis in type 1 diabetes is not adversely affected by SGLT2 inhibitor therapy","volume":"21","author":"Siebel","year":"2019","journal-title":"Diabetes Technol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_14","first-page":"e17093","article-title":"Sodium-Glucose Co-transporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Bariatric Surgery: A Case and Literature Review","volume":"13","author":"Kapila","year":"2021","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11892-024-01537-3","article-title":"Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: A Review","volume":"24","author":"Pishdad","year":"2024","journal-title":"Curr. Diab. Rep."},{"key":"ref_16","first-page":"307","article-title":"Genito Urinary Infection and Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Receiving SGLT2 Inhibitors: Evidence from a Systematic Literature Review of Landmark Randomized Clinical Trial","volume":"7","author":"Arshad","year":"2024","journal-title":"Drug Res."},{"key":"ref_17","first-page":"e13665","article-title":"Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers","volume":"13","author":"Somagutta","year":"2021","journal-title":"Cureus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.4239\/wjd.v14.i8.1314","article-title":"Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports","volume":"14","author":"Juneja","year":"2023","journal-title":"World J. Diabetes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11892-020-01307-x","article-title":"Euglycemic Ketoacidosis","volume":"20","author":"Bonora","year":"2020","journal-title":"Curr. Diab. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00592-022-02015-6","article-title":"SGLT-2 inhibitors and euglycemic diabetic ketoacidosis\/diabetic ketoacidosis in FAERS: A pharmacovigilance assessment","volume":"60","author":"He","year":"2023","journal-title":"Acta Diabetol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajem.2021.01.033","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2i use: Case series","volume":"44","author":"Puls","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/MS9.0000000000000479","article-title":"Severe euglycemic diabetic ketoacidosis secondary to sodium-glucose co-transporter 2 inhibitor: Case report and literature review","volume":"85","author":"ElRishi","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e10242","DOI":"10.1002\/jbm4.10242","article-title":"Mineral and Electrolyte Disorders with SGLT2i Therapy","volume":"3","author":"Cianciolo","year":"2019","journal-title":"JBMR Plus"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Cianciolo, G., De Pascalis, A., Gasperoni, L., Tondolo, F., Zappulo, F., Capelli, I., Cappuccilli, M., and Manna, G. (2020). La The Off Target Effects, Electrolyte and Mineral Disorders of SGLT2i. Molecules, 25.","DOI":"10.3390\/molecules25122757"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.34067\/KID.0006672021","article-title":"Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials","volume":"3","author":"Zhang","year":"2022","journal-title":"Kidney360"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13098-020-0515-x","article-title":"Enhancement of the serum chloride concentration by administration of sodium-glucose cotransporter-2 inhibitor and its mechanisms and clinical significance in type 2 diabetic patients: A pilot study","volume":"12","author":"Kataoka","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ejhf.1068","article-title":"The mechanism of action of sodium\u2013glucose co-transporter 2 inhibitors is similar to carbonic anhydrase inhibitors","volume":"20","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6615624","DOI":"10.1155\/2023\/6615624","article-title":"Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases","volume":"2023","author":"Stamatiades","year":"2023","journal-title":"Int. J. Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s11096-021-01256-9","article-title":"Sodium-glucose co-transporter 2 inhibitors in COVID-19: Meeting at the crossroads between heart, diabetes and infectious diseases","volume":"43","author":"Koufakis","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_30","first-page":"e25818","article-title":"A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis","volume":"14","author":"Sharma","year":"2022","journal-title":"Cureus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/ccr3.2147","article-title":"Euglycemic diabetic ketoacidosis in association with dapagliflozin use after gastric sleeve surgery in a patient with type II diabetes mellitus","volume":"7","author":"Banakh","year":"2019","journal-title":"Clin. Case Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5662\/wjm.v6.i2.133","article-title":"Methods, units and quality requirements for the analysis of haemoglobin A 1c in diabetes mellitus","volume":"6","author":"Holm","year":"2016","journal-title":"World J. Methodol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1177\/00033197221129358","article-title":"Relationship Between Serum Endocan Levels and Other Predictors of Endothelial Dysfunction in Obese Women","volume":"74","author":"Mercantepe","year":"2022","journal-title":"Angiology"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1553\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:35:39Z","timestamp":1760114139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ph17111553"],"URL":"https:\/\/doi.org\/10.3390\/ph17111553","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]}}}